| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 90 | 2022 |
| Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 48 | 2021 |
| Plasma circulating tumor DNA and clonal hematopoiesis in metastatic renal cell carcinoma JVW Bacon, M Annala, M Soleimani, JM Lavoie, A So, ME Gleave, L Fazli, ... Clinical Genitourinary Cancer 18 (4), 322-331. e2, 2020 | 41 | 2020 |
| Frequent mutation of the FOXA1 untranslated region in prostate cancer M Annala, S Taavitsainen, G Vandekerkhove, JVW Bacon, K Beja, KN Chi, ... Communications biology 1 (1), 122, 2018 | 26 | 2018 |
| Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer SG Dugas, DC Müller, C Le Magnen, J Federer‐Gsponer, HH Seifert, ... Cancer cytopathology 127 (9), 578-585, 2019 | 17 | 2019 |
| A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC) KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, ... Annals of Oncology 29, viii271-viii272, 2018 | 11 | 2018 |
| Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy JVW Bacon, DC Müller, E Ritch, M Annala, SG Dugas, C Herberts, ... European Urology Oncology 5 (6), 677-686, 2022 | 8 | 2022 |
| Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC. KN Chi, S Taavitsainen, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, ... Journal of Clinical Oncology 37 (15_suppl), 5003-5003, 2019 | 6 | 2019 |
| A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes EJ Ritch, C Herberts, EW Warner, SWS Ng, EM Kwan, JVW Bacon, ... NPJ Precision Oncology 7 (1), 27, 2023 | 5 | 2023 |
| TP53 alterations are associated with poor survival in patients with primary mediastinal nonseminoma germ cell tumors JVW Bacon, P Giannatempo, G Cataldo, L Fazli, N Saxena, G Ozgun, ... The Oncologist 27 (11), e912-e915, 2022 | 5 | 2022 |
| Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy. E Schönlau, DC Müller, G Vandekerkhove, A Murtha, JVW Bacon, C Wells, ... Journal of Clinical Oncology 41 (16_suppl), 4577-4577, 2023 | 2 | 2023 |
| Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma. L Nappi, J Bacon, M Annala, M Soleimani, JM Lavoie, KN Chi, AW Wyatt, ... Journal of Clinical Oncology 37 (15_suppl), e16105-e16105, 2019 | 1 | 2019 |
| Genomic characterization of urologic malignancies and the relevance of clonal hematopoiesis in liquid biopsies JVW Bacon University of British Columbia, 2023 | | 2023 |
| Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing C Herberts, M Annala, J Sipola, SW Ng, XE Chen, A Nurminen, ... Cancer Research 82 (12_Supplement), 3625-3625, 2022 | | 2022 |
| Somatic features of response and relapse in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin DC Muller, JVW Bacon, E Ritch, SG Dugas, G Vandekerkhove, M Annala, ... EUROPEAN UROLOGY 79, S617-S617, 2021 | | 2021 |
| Plasma circulating tumor DNA is scarce and confounded by clonal hematopoiesis in metastatic renal cell carcinoma JVW Bacon, M Annala, M Soleimani, JM Lavoie, AI So, ME Gleave, L Fazli, ... CLINICAL CANCER RESEARCH 26 (11), 43-43, 2020 | | 2020 |
| Abstract A18: Plasma circulating tumor DNA is scarce and confounded by clonal hematopoiesis in metastatic renal cell carcinoma JVW Bacon, M Annala, M Soleimani, JM Lavoie, AI So, ME Gleave, L Fazli, ... Clinical Cancer Research 26 (11_Supplement), A18-A18, 2020 | | 2020 |
Alexander WyattAssociate Professor, University of British ColumbiaVerified email at prostatecentre.com
